Glenmark Pharmaceuticals (NSE:GLENMARK) Other Current Receivables: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLENMARK Glenmark Pharmaceuticals Ltd NSE:GLENMARK
84 GF Score
Price ₹2,290.00
GF Value ₹2,216.40
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Glenmark Pharmaceuticals Other Current Receivables?

Glenmark Pharmaceuticals NSE:GLENMARK +0.62% 84 Other Current Receivables is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:GLENMARK with a GF Score™ of 84/100 and a GF Value™ of ₹2,216.40 (Fairly Valued). The stock has 2 warning signs investors should review.

Glenmark Pharmaceuticals's Other Current Receivables for the quarter that ended in Jun. 2026 was ₹0 Mil.

Glenmark Pharmaceuticals's annual Other Current Receivables declined from Mar. 2024 (₹1,451.71 Mil) to Mar. 2025 (₹303.07 Mil) and declined from Mar. 2025 (₹303.07 Mil) to Mar. 2026 (₹0.00 Mil).

Glenmark Pharmaceuticals Other Current Receivables Related Terms

Glenmark Pharmaceuticals Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Glenmark Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals Other Current Receivables Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 504.59 840.98 1,451.71 303.07 0.00

Glenmark Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:GLENMARK
84GF Score
Glenmark Pharmaceuticals Ltd NSE:GLENMARK
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glenmark Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ₹0 Mil mean?
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Other Current Receivables of ₹0 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Glenmark Pharmaceuticals and its competitors.
Is Glenmark Pharmaceuticals' Other Current Receivables too high?
Glenmark Pharmaceuticals' current Other Current Receivables is ₹0 Mil. Overall, Glenmark Pharmaceuticals has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Other Current Receivables compare to ZTS?
Glenmark Pharmaceuticals' Other Current Receivables of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Glenmark Pharmaceuticals and its competitors. Glenmark Pharmaceuticals's current Other Current Receivables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,216.40, compared to a current price of ₹2,290.00 — trading 3.3% above its estimated fair value. The current Other Current Receivables is ₹0 Mil. Glenmark Pharmaceuticals' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Other Current Receivables is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?

Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,290.00 is trading 3.3% above its estimated GF Value™ of ₹2,216.40. GuruFocus considers Glenmark Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLENMARK:

  • Other Current Receivables: ₹0 Mil
  • GF Value™: ₹2,216.40 vs. price of ₹2,290.00 (3.3% above fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glenmark Pharmaceuticals Business Description

Other Exchanges 532296:India
Address B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
84GF Score

Get the complete analysis for NSE:GLENMARK

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,290.00
Price
₹2,216.40
GF Value